Zelapar Tablet, Orally Disintegrating
Product Images NDC 0187-0453

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Zelapar (NDC 0187-0453). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bausch Health Us, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 01

Chemical structure of selegiline hydrochloride, the active ingredient in ZELAPAR 1.25 mg orally disintegrating tablets by Bausch Health US, LLC.*

FDA Label Image

Image 02

A line graph titled 'Mean Daily % OFF Time During Treatment' compares the mean percentage of OFF time over 12 study weeks for Zelapar versus placebo. The x-axis represents study weeks from 0 to 12, and the y-axis shows mean % OFF time ranging from 25 to 45. Zelapar shows a decreasing OFF time trend, indicating improvement, while placebo remains relatively stable with minor fluctuations.*

FDA Label Image

Image 03

Packaging label for Zelapar (Selegiline HCL) orally disintegrating tablets, 1.25 mg strength. The label indicates a package containing 60 tablets in clear child-resistant pouches, distributed by Bausch Health US, LLC. Directions and storage instructions are printed, along with a designated area for a dispensing label. The label includes usage warnings and manufacturer information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.